Patents by Inventor Marvin L. Bayne

Marvin L. Bayne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA molecules encoding vascular endothelial cell growth factor II subunits
    Patent number: 6933134
    Abstract: Vascular endothelial cell growth factor II is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer, stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: August 23, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Marvin L. Bayne, Gregory L. Conn, Kenneth A. Thomas, Jr.
  • Vascular endothelial cell growth factor C subunit
    Patent number: 6569434
    Abstract: Vascular endothelial cell growth factor C subunit DNA is prepared by polymerase chain reaction techniques. The DNA encodes a protein that may exist as either a heterodimer or homodimer. The protein is a mammalian vascular endothelial cell mitogen and as such is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: May 27, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Marvin L. Bayne, Kenneth A. Thomas, Jr.
  • DNA molecules encoding vascular endothelial cell growth factor II subunits
    Publication number: 20030045471
    Abstract: Vascular endothelial cell growth factor II is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer, stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
    Type: Application
    Filed: February 8, 2002
    Publication date: March 6, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Marvin L. Bayne, Gregory L. Conn, Kenneth A. Thomas
  • Vascular endothelial cell growth factor II
    Patent number: 6180107
    Abstract: Vascular endothelial cell growth factor II is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer, stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
    Type: Grant
    Filed: March 10, 1998
    Date of Patent: January 30, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Marvin L. Bayne, Gregory L. Conn, Kenneth A. Thomas, Jr.
  • Vascular endothelial cell growth factor C subunit
    Patent number: 6140073
    Abstract: Vascular endothelial cell growth factor C subunit DNA is prepared by polymerase chain reaction techniques. The DNA encodes a protein that may exist as either a heterodimer or homodimer. The protein is a mammalian vascular endothelial cell mitogen and as such is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
    Type: Grant
    Filed: January 16, 1996
    Date of Patent: October 31, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Marvin L. Bayne, Kenneth A. Thomas, Jr.
  • Vascular endothelial cell growth factor C subunit
    Patent number: 5994300
    Abstract: Vascular endothelial cell growth factor C subunit DNA is prepared by polymerase chain reaction techniques. The DNA encodes a protein that may exist as either a heterodimer or homodimer. The protein is a mammalian vascular endothelial cell mitogen and as such is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
    Type: Grant
    Filed: September 20, 1993
    Date of Patent: November 30, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Marvin L. Bayne, Kenneth A. Thomas, Jr.
  • Vascular endothelial cell growth factor II
    Patent number: 5726152
    Abstract: Vascular endothelial cell growth factor II is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer, stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
    Type: Grant
    Filed: August 31, 1994
    Date of Patent: March 10, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Marvin L. Bayne, Gregory L. Conn, Kenneth A. Thomas, Jr.
  • Purification and characterization of a glioma-derived growth factor having vascular endothelial cell growth promoting activity
    Patent number: 5532343
    Abstract: Glioma-derived growth factor is purified from the culture media used to maintain mammalian glioma cells. The protein stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
    Type: Grant
    Filed: March 2, 1994
    Date of Patent: July 2, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Marvin L. Bayne, Kenneth A. Thomas, Jr., Gregory L. Conn
  • DNA encoding glioma-derived growth factor having vascular endothelial cell growth promoting activity
    Patent number: 5338840
    Abstract: Glioma-derived growth factor is purified from the culture media used to maintain mammalian glioma cells. The protein stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
    Type: Grant
    Filed: May 27, 1992
    Date of Patent: August 16, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Marvin L. Bayne, Kenneth A. Thomas, Jr., Gregory L. Conn
  • Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
    Patent number: 4876242
    Abstract: A synthetic gene encoding a 71-amino acid analog of human insulin-like grouwth factor (hIGF-I) has been constructed and expressed in the yeast, Saccharomyces cerevisiae. The protein analog, IGF132, contains the first 17 amino acids of the B chain of human insulin in place of the first 16 amino acids of hIGF-I. The purified hybrid protein has high affinity for the type I IGF recepto (12 nM) yet has drastically reduced affinity for human serum carrier proteins (>1000 nM). This analog is 5 to 10 times more active than normal hIGF-I in stimulating DNA synthesis in 3T3 cells and is a more active growth factor in vivo due to its reduced affinity for serum carrier proteins. Other proteins with similar properties have also been constructed.
    Type: Grant
    Filed: September 21, 1987
    Date of Patent: October 24, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Joy D. Applebaum, Marvin L. Bayne, Margaret A. Cascieri